Costeff Syndrome (3-methylglutaconic aciduria type III) is a rare genetic condition causing early-onset optic atrophy along with movement difficulties such as chorea and spasticity later in life. Genetic testing and specialized metabolic/neuro-ophthalmology care for this condition are essentially unavailable within Uganda. Optic Atrophy Treatment Center works with Ugandan families exploring stem cell therapy for the optic nerve component of Costeff Syndrome.
As an extremely rare metabolic-genetic condition, Costeff Syndrome requires specialized diagnostic testing (urine organic acid analysis, genetic testing for the OPA3 gene) that is not available within Uganda. Families often travel abroad for both diagnostic confirmation and to explore treatment options for the optic nerve damage.

Associate Professor, Vitreo-Retina Surgeon. 10+ Years Experience

Senior Consultant Ophthalmologist & Eye Surgeon· 26+ yrs experience

Consultant Ophthalmologist & Eye Surgeon, MD, DO .16+ Years Experience
Stem cell therapy is studied for its potential to help support optic nerve tissue affected by Costeff Syndrome. It addresses the vision component only — the movement-related features (chorea, spasticity) require ongoing management by a neurologist.
Suitability depends on the stage and cause of the condition. Before travelling, our team reviews:

Excellent customer service and straight away got some improvement as my eye points stop hurting when i press them so and still on the healing process. Very experienced doctor and lovely people. Happy with it.

I came from overseas specifically for treatment. The staff not only assisted me with transport but also made the whole experience hassle-free. The medical service was of the highest standard and I was very secure in Delhi.
“No, our evaluation and treatment address the optic nerve/vision component only. Movement-related symptoms should be managed by a neurologist.”
” It’s helpful if available, but not mandatory — our team can review based on clinical history and OCT/visual field findings.”
“OCT scan, visual field test, any metabolic/genetic test results, and a summary of when vision loss and movement symptoms began.”

We would love to hear from you! Please fill out the form below.